Anticuerpos monoclonales CTLA4

Los anticuerpos monoclonales CTLA4 Hacen parte de la membrana de los linfocitos T, mira este vídeo para que aprendas su mecanismo de acción.

Bibliografía:
1. Gulley, J. L., & Dahut, W. L. (2007). Future directions in tumor immunotherapy: CTLA4 blockade. Nature Clinical Practice Oncology
2. Alegre, M.-L., Frauwirth, K. A., & Thompson, C. B. (2001). T-cell regulation by CD28 and CTLA-4. Nature Reviews Immunology.
3. Gulley, J. L., & Dahut, W. L. (2007). Future directions in tumor immunotherapy: CTLA4 blockade. Nature Clinical Practice Oncology.
4. Wei, S. C., Duffy, C. R., & Allison, J. P. (2018). Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery.
5. Kailashiya, V., Sharma, H. B., & Kailashiya, J. (2019). Role of CTLA4 A49G polymorphism in systemic lupus erythematosus and its geographical distribution. Journal of Clinical Pathology.